Foundation Medicine Inc (FMI)

41.25
0.35 0.86
NASDAQ : Health Care
Prev Close 40.90
Open 41.10
Day Low/High 40.50 / 41.70
52 Wk Low/High 13.34 / 33.31
Volume 39.44K
Avg Volume 231.60K
Exchange NASDAQ
Shares Outstanding 35.64M
Market Cap 1.52B
EPS -3.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Monday Option Activity: FMI, DVAX, VICR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Foundation Medicine Inc , where a total volume of 6,347 contracts has been traded thus far today, a contract volume which is representative of approximately 634,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 245.1% of FMI's average daily trading volume over the past month, of 258,995 shares.

Foundation Medicine To Present At Upcoming Investor Conferences

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the following upcoming investor conferences: Goldman Sachs Annual Healthcare...

Foundation Medicine And Its Collaborators To Present New Data At ASCO 2017 Supporting The Integration Of Comprehensive Genomic Profiling (CGP) In Personalized Clinical Care In Oncology

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that data from its suite of comprehensive genomic profiling (CGP) assays, including FoundationOne ®, FoundationACT ® liquid biopsy, FoundationOne ®...

Foundation Medicine Announces 2017 First Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its first quarter ended March 31, 2017.

Foundation Medicine Announces Timing For First Quarter 2017 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's first quarter ended March 31, 2017 will be released on Tuesday, May 9, 2017.

Bristol-Myers Squibb Enters Collaboration To Leverage Foundation Medicine's Molecular Information Platform To Identify Predictive Biomarkers Across Multiple Tumor Types And Immunotherapy Agents

Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine's comprehensive genomic profiling and molecular information solutions...

Foundation Medicine Receives Medicare Payment In Non-Small Cell Lung Cancer Under A Local Coverage Determination For FoundationOne®, The Company's Comprehensive Genomic Profiling Assay

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has received payment from Palmetto GBA, the Company's Medicare Administrative Contractor (MAC) in North Carolina, for its FoundationOne comprehensive...

Foundation Medicine To Present At Cowen And Company's 37th Annual Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at Cowen & Company's 37 th Annual Healthcare Conference on Monday, March 6, 2017, at 4:40 p.

Foundation Medicine Announces 2016 Fourth Quarter And Year-End Results, Recent Highlights And 2017 Outlook

Foundation Medicine (NASDAQ:FMI) today reported financial and operational results for the fourth quarter and year ended December 31, 2016.

Foundation Medicine Announces Timing For Fourth Quarter And Year-End 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2016 will be released on Wednesday, February 22, 2017.

Commit To Purchase Foundation Medicine At $17.50, Earn 21.6% Annualized Using Options

Investors considering a purchase of Foundation Medicine Inc stock, but cautious about paying the going market price of $19.62/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $17.50 strike, which has a bid at the time of this writing of $2.05.

Foundation Medicine Reports Preliminary 2016 Results

Foundation Medicine Reports Preliminary 2016 Results

Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $28.

Proven Biopharma Executive And Commercial Leader, Troy Cox, Named As Chief Executive Officer Of Foundation Medicine. (Photo: Business Wire)

Proven Biopharma Executive And Commercial Leader, Troy Cox, Named As Chief Executive Officer Of Foundation Medicine. (Photo: Business Wire)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that, as part of the succession of its executive leadership, the Board of Directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief...

Foundation Medicine To Present At The 35th Annual J.P. Morgan Healthcare Conference

Foundation Medicine To Present At The 35th Annual J.P. Morgan Healthcare Conference

Foundation Medicine (NASDAQ:FMI) today announced that Michael J.

Foundation Medicine Enters Oversold Territory (FMI)

Foundation Medicine Enters Oversold Territory (FMI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Foundation Medicine

Relative Strength Alert For Foundation Medicine

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Flatiron Health And Foundation Medicine Unveil Powerful Oncology Information Resource To Advance Precision Medicine

Flatiron Health And Foundation Medicine Unveil Powerful Oncology Information Resource To Advance Precision Medicine

Flatiron Health and Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted...

Foundation Medicine Announces 2016 Third Quarter Results And Recent Highlights

Foundation Medicine Announces 2016 Third Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its third quarter ended September 30, 2016.

Commit To Purchase Foundation Medicine At $20, Earn 18.7% Annualized Using Options

Commit To Purchase Foundation Medicine At $20, Earn 18.7% Annualized Using Options

Investors considering a purchase of Foundation Medicine Inc stock, but tentative about paying the going market price of $23.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $20 strike, which has a bid at the time of this writing of $2.05.

Foundation Medicine And Sarah Cannon Collaborate To Advance Personalized Medicine For Patients With Cancer

Foundation Medicine And Sarah Cannon Collaborate To Advance Personalized Medicine For Patients With Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) and Sarah Cannon Research Institute (Sarah Cannon) today announced a collaboration focused on advancing personalized medicine utilizing molecular information for patients across...

Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty To Its Board Of Directors

Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty To Its Board Of Directors

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the election of Michael R.

Foundation Medicine Announces Timing For Third Quarter 2016 Financial Results And Conference Call

Foundation Medicine Announces Timing For Third Quarter 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2016, will be released on Wednesday, November 2, 2016.

Foundation Medicine To Present At The Morgan Stanley Global Healthcare Conference

Foundation Medicine To Present At The Morgan Stanley Global Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016, at 5:25 p.

Foundation Medicine Adds New Immunotherapy Features To Its Market-Leading Products

Foundation Medicine Adds New Immunotherapy Features To Its Market-Leading Products

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the addition of new clinical markers to its FoundationOne ® and FoundationOne ® Heme products, which are designed to enhance oncologists' insight into...

Foundation Medicine Announces 2016 Second Quarter Results And Recent Highlights

Foundation Medicine Announces 2016 Second Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2016.

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

Foundation Medicine, Inc. (NASDAQ: FMI) today announced that the U.

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Investors eyeing a purchase of Foundation Medicine Inc shares, but tentative about paying the going market price of $23.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $15 strike, which has a bid at the time of this writing of 75 cents.